VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Amneal Pharmaceuticals Executive Compensation (FY25)

AMRX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Chirag Patel
Latest say-on-pay support
=
May 6, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Amneal Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 7, 2026
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Amneal Pharmaceuticals brief$500Get the executive brief
Velarion Intel, one year, every company
304 figures on this page: 297 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Chirag Patel: $7,187,970 → $8,691,745 (20.9% higher)
CEO pay ratio: 595:1 → 679:1 (14.1% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Amneal Pharmaceuticals' chief executive and what were they paid?
Chirag Patel, Co-Chief Executive Officer and President, received $8,691,745 in total compensation for fiscal 2025. Compared with the $7,187,970 reported for fiscal 2024, Patel's total was 20.9% higher.
What was Amneal Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 99.0% of votes cast including abstentions in favor at the meeting held May 6, 2026.
Which companies are in Amneal Pharmaceuticals' peer group?
The disclosed peer group includes Alkermes plc, Amphastar Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., Emergent BioSolutions Inc. and Jazz Pharmaceuticals plc, among others.
What is Amneal Pharmaceuticals' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 679:1, against median employee compensation of $12,853.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chintu Patel
Co-Chief Executive Officer
◇—◇—◇—◇◇
Anastasios Konidaris
EVP & Chief Financial Officer
◇—◇—◇—◇◇
Andrew Boyer
EVP, Chief Commercial Officer - Generics
◇—◇—◇—◇◇
Nikita Shah
EVP, Chief Human Resources Officer
◇—◇—◇—◇◇
Jason Daly
EVP, Chief Legal Officer & Secretary
◇◇◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chintu Patel
Co-Chief Executive Officer
◇—◇—◇—◇◇
Andrew Boyer
EVP, Chief Commercial Officer - Generics
◇—◇—◇—◇◇
Anastasios Konidaris
EVP & Chief Financial Officer
◇—◇—◇—◇◇
Nikita Shah
EVP, Chief Human Resources Officer
◇—◇—◇—◇◇
Jason Daly
EVP, Chief Legal Officer & Secretary
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chirag Patel
Co-Chief Executive Officer and President
◇—◇—◇—◇◇
Anastasios Konidaris
EVP & Chief Financial Officer
◇—◇—◇—◇◇
Andrew Boyer
EVP, Chief Commercial Officer - Generics
◇—◇—◇—◇◇
Jason Daly
EVP, Chief Legal Officer & Secretary
◇—◇—◇—◇◇
Nikita Shah
EVP, Chief Human Resources Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Chirag Patel
Co-Chief Executive Officer and President
◇—◇—◇—◇◇
Anastasios Konidaris
EVP & Chief Financial Officer
◇—◇—◇—◇◇
Andrew Boyer
EVP, Chief Commercial Officer - Generics
◇—◇—◇—◇◇
Jason Daly
EVP, Chief Legal Officer & Secretary
◇—◇—◇—◇◇
Nikita Shah
EVP, Chief Human Resources Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Anastasios KonidarisRSU◇——◇——◇
Anastasios KonidarisPSU◇◇◇—◇—◇
Andrew BoyerRSU◇——◇——◇
Andrew BoyerPSU◇◇◇—◇—◇
Chintu PatelRSU◇——◇——◇
Chintu PatelPSU◇◇◇—◇—◇
Chirag PatelPSU◇◇◇—◇—◇
Chirag PatelRSU◇——◇——◇
Jason DalyPSU◇◇◇—◇—◇
Jason DalyRSU◇——◇——◇
Nikita ShahPSU◇◇◇—◇—◇
Nikita ShahRSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Chirag PatelPSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Anastasios KonidarisPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Andrew BoyerPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Nikita ShahPSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Jason DalyPSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Anastasios Konidaris
EVP & Chief Financial Officer · Amended agreement
Severance multiple◇
Severance base◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Chirag Patel
Chief Executive Officer · Severance agreement
Clawback◇
Jason Daly
EVP, Chief Legal Officer & Secretary · Terms as described in the company’s compensation discussion
Severance cash amount◇
Nikita Shah
EVP, Chief Human Resources Officer · Amended agreement
Severance multiple◇
Severance base◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Emily Peterson Alva
◇◇———◇◇
Paul Meister
Board chair
◇◇————◇
John Kiely
◇◇———◇◇
Jeff George
◇◇———◇◇
Ted Nark
◇◇———◇◇
J. Kevin Buchi
◇◇————◇
Shlomo Yanai
◇◇———◇◇
Deb Autor
◇◇————◇
Gautam Patel
◇◇———◇◇
Chirag Patel and Chintu Patel served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alkermes plc ALKS
  • Amphastar Pharmaceuticals, Inc. AMPH
  • ANI Pharmaceuticals, Inc. ANIP
  • Emergent BioSolutions Inc. EBS
  • Jazz Pharmaceuticals plc JAZZ
  • Neurocrine Biosciences, Inc. NBIX
  • Pacira BioSciences, Inc. PCRX
  • Perrigo Company plc PRGO
  • Prestige Consumer Healthcare Inc. PBH
  • Supernus Pharmaceuticals, Inc. SUPN
  • United Therapeutics Corporation UTHR
  • Viatris Inc. VTRS

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 6, 2026=◇◇◇
2024May 6, 2025=◇◇◇
2023May 2, 2024=◇◇◇
2022May 9, 2023=◇◇◇
2021May 9, 2022=◇◇◇
2020May 5, 2021=◇◇◇
2019May 5, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Chirag Patel (Co-Chief Executive Officer and President), FY2025 total compensation $8,691,745 (base salary $800,000) [exec_comp, SEC accession 0001308179-26-000143, filed 2026-03-25]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Amneal Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Amneal Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Amneal Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Amneal Pharmaceuticals' disclosed peer group is defensible, who names Amneal Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
304 figures on this page: 297 cited to the filing that reported them, 7 calculated from figures it prints.
297 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001628280-26-032137
  2. 0001308179-26-000143
    CEO Pay Ratio · Director Compensation · Grants of Plan Based Awards in 2025 · Outstanding Equity Awards at December 31, 2025 · and 2 more sections
  3. 0001723128-25-000024
  4. 0001308179-25-000220
    Summary Compensation Table
  5. 0001628280-24-021107
  6. 0001308179-24-000231
    Summary Compensation Table
  7. 0001723128-23-000023
  8. 0001723128-22-000019
  9. 0001193125-21-156284
  10. 0001723128-20-000013
  11. 0001193125-20-136972
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Amneal Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AMRX (accessed 2026).
Short form: data: Velarion

The Amneal Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Amneal Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Amneal Pharmaceuticals discloses

The companies named in AMRX's own disclosed peer group.

Alkermes plcAmphastar Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc.Emergent BioSolutions Inc.Jazz Pharmaceuticals plcNeurocrine Biosciences, Inc.Pacira BioSciences, Inc.Perrigo Company plcPrestige Consumer Healthcare Inc.Supernus Pharmaceuticals, Inc.United Therapeutics CorporationViatris Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy